Ipsen gives back Parkin­son’s drug af­ter fail­ing PhI­Ib study; Par­a­digm Ther­a­peu­tics gets glob­al rights to skin treat­ment

IR­LAB Ther­a­peu­tics has full rights to mes­dopetam again af­ter the drug flunked a Phase IIb study in­volv­ing Parkin­son’s pa­tients.

The com­pa­nies were test­ing mes­dopetam among pa­tients with lev­odopa-in­duced dysk­i­ne­sias, or se­vere in­vol­un­tary move­ments af­ter Ipsen paid $28 mil­lion up­front in 2021 to li­cense the drug. While not a symp­tom of Parkin­son’s dis­ease it­self, dysk­i­ne­sia is of­ten as­so­ci­at­ed with the most com­mon­ly pre­scribed Parkin­son’s treat­ment, lev­odopa, al­so sold un­der brand names like Duopa and Sinemet.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER